A
Allogene Therapeutics, Inc. (ALLO)
NMS – Real vaqt narxi. Valyuta: USD
2.26
-0.15 (-6.22%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.27
+0.01 (0.44%)
Bozordan keyin: Mar 27, 2026, 7:51 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
2.26
-0.15 (-6.22%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.27
+0.01 (0.44%)
Bozordan keyin: Mar 27, 2026, 7:51 PM EDT
Allogene Therapeutics, Inc. – bu saraton va autoimmun kasalliklarni davolash uchun genetik jihatdan muhandislik qilingan allogen T-hujayrali terapiyalarni ishlab chiqish va tijoratlashtiruvchi klinik bosqichdagi immuno-onkologiya kompaniyasi. U oqsil muhandisligi, gen tahrirlash, gen qo'shish va ilg'or patentlangan T-hujayra ishlab chiqarish texnologiyalaridan foydalangan holda, bir nechta allogen CAR T-hujayrali mahsulot nomzodlaridan iborat bir qatorni ishlab chiqadi. Kompaniya, shuningdek, katta B-hujayrali limfomani (LBCL) davolash uchun CD19ni nishonga oladigan muhandislik qilingan allogen CAR T-hujayrali mahsulot nomzodi bo'lgan cemacabtagene ansegedleucel (cema-cel)ni ishlab chiqmoqda. Bundan tashqari, u buyrak hujayrali karsinomani (RCC) davolash uchun CD70ni nishonga oladigan muhandislik qilingan allogen CAR T-hujayrali mahsulot nomzodi bo'lgan ALLO-316ni; va tizimli lupus eritematoz (SLE), idiopatik yallig'lanishli miyopatiyalar (IIM) va tizimli skleroz (SSc) kabi autoimmun kasalliklarni (AID) davolash uchun CD19 va CD70 ikkalasini ham nishonga oladigan muhandislik qilingan allogen CAR T-hujayrali mahsulot nomzodi bo'lgan ALLO-329ni ishlab chiqmoqda. Kompaniya 2017 yilda ro'yxatga olingan va uning shtab-kvartirasi Janubiy San-Fransisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Zachary J. Roberts M.D., Ph.D. | Executive VP of Research & Development and Chief Medical Officer |
| Mr. Benjamin M. Beneski | Senior VP & Chief Technical Officer |
| Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary |
| Mr. Geoffrey M. Parker | Executive VP & CFO |
| Mr. Joshua A. Kazam | Co-Founder & Director |
| Ms. Annie Yoshiyama | SVP & Corporate Controller |
| Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer |
| Ms. Susan R. Lundeen | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-12 | 8-K | allo-20260312.htm |
| 2025-11-06 | 8-K | allo-20251106.htm |
| 2025-10-14 | 8-K | allo-20250926.htm |
| 2025-08-13 | 8-K | allo-20250813.htm |
| 2025-08-01 | 8-K | d75167d8k.htm |
| 2025-06-23 | 8-K | allo-20250618.htm |
| 2025-05-13 | 10-Q | allo-20250331.htm |
| 2025-04-30 | ARS | allo-20241231x10k.pdf |
| 2025-03-13 | 10-K | allo-20241231.htm |
| 2025-02-25 | 8-K | d926019d8k.htm |